We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $189M Turnover 22.11%
1-Year Est. Return 67.72%
This Fund
S&P 500
This Quarter Est. Return
+14.16%
1 Year Est. Return
+67.72%
3 Year Est. Return
+169.37%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$277M
AUM Growth
-$8.05M
Cap. Flow
-$5.69M
Cap. Flow %
-2.06%
Top 10 Hldgs %
77.48%
Holding
98
New
6
Increased
9
Reduced
11
Closed
9
Avg Time Held
2 years
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1.3 years

Top Buys

Rank Stock Value
1
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$25.7M
2
COLL icon
Collegium Pharmaceutical
COLL
+$1.09M
3
PFE icon
Pfizer
PFE
+$814K
4
MDT icon
Medtronic
MDT
+$693K
5
HELP
Helus Pharma Inc. Common Stock
HELP
+$614K

Top Sells

Rank Stock Value
1
CLMT icon
Calumet Specialty Products
CLMT
+$14.2M
2
CLOZ icon
Panagram BBB-B CLO ETF
CLOZ
+$13.3M
3
GSK icon
GSK
GSK
+$2.66M
4
DMRC icon
Digimarc Corp
DMRC
+$2.25M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.89M

Sector Composition

Rank Sector Weight
1 Materials 29.62%
2 Healthcare 26.2%
3 Financials 16.91%
4 Miscellaneous 16.47%
5 Communication Services 7.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CLMT icon
1
Calumet Specialty Products
CLMT
$5.06B
$80.4M 29.08%
3,651,361
-673,639
-16% -$14.2M
2021 Q4
12 quarters
APO icon
2
Apollo Global Management
APO
$67B
$37.2M 13.44%
225,000
– –
2021 Q4
12 quarters
JAAA icon
3
Janus Henderson AAA CLO ETF
JAAA
$32.1B
$29.9M 10.83%
590,397
+505,568
+596% +$25.7M
2023 Q3
5 quarters
GOOG icon
4
Alphabet (Google) Class C
GOOG
$4.2T
$21.4M 7.73%
112,220
– –
2021 Q4
12 quarters
DCGO icon
5
DocGo
DCGO
$26.9M
$13M 4.71%
3,070,850
– –
2021 Q4
12 quarters
VRNA
6
DELISTED
Verona Pharma
VRNA
$7.4M 2.68%
159,300
-20,700
-12% -$777K
2023 Q4
4 quarters
PFE icon
7
Pfizer
PFE
$166B
$6.75M 2.44%
254,537
+30,000
+13% +$814K
2021 Q4
12 quarters
ICLO icon
8
Invesco AAA CLO Floating Rate Note ETF
ICLO
$604M
$5.17M 1.87%
201,487
+12,600
+7% +$323K
2023 Q3
5 quarters
JPM icon
9
JPMorgan Chase
JPM
$890B
$5.03M 1.82%
20,985
– –
2021 Q4
12 quarters
CPRX icon
10
DELISTED
Catalyst Pharmaceutical
CPRX
$4.38M 1.58%
210,000
-2,000
-0.9% -$43K
2023 Q4
4 quarters
TVTX icon
11
Travere Therapeutics
TVTX
$5.02B
$3.97M 1.44%
228,000
-30,231
-12% -$535K
2023 Q3
5 quarters
OABI icon
12
OmniAb
OABI
$662M
$3.87M 1.4%
1,094,505
-54,000
-5% -$214K
2022 Q4
8 quarters
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$3.65M 1.32%
346,904
+14,904
+4% +$181K
2021 Q4
12 quarters
XERS icon
14
Xeris Biopharma Holdings
XERS
$1.78B
$3.39M 1.23%
1,000,000
– –
2023 Q4
4 quarters
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$2.06B
$3.31M 1.2%
440,000
+58,000
+15% +$440K
2024 Q2
2 quarters
ARDX icon
16
Ardelyx
ARDX
$824M
$3.1M 1.12%
612,270
-70,597
-10% -$390K
2022 Q3
9 quarters
ESGR icon
17
DELISTED
Enstar Group
ESGR
$2.42M 0.87%
7,500
– –
2024 Q1
3 quarters
IMVT icon
18
Immunovant
IMVT
$5.76B
$2.28M 0.82%
92,000
– –
2023 Q4
4 quarters
CSX icon
19
CSX Corp
CSX
$89.4B
$2.26M 0.82%
70,000
– –
2022 Q4
8 quarters
PTGX icon
20
Protagonist Therapeutics
PTGX
$8.82B
$2.02M 0.73%
52,368
– –
2023 Q3
5 quarters
INZY icon
21
DELISTED
Inozyme Pharma
INZY
$1.93M 0.7%
695,000
+130,451
+23% +$496K
2023 Q1
7 quarters
AB icon
22
AllianceBernstein
AB
$3.16B
$1.78M 0.64%
48,000
– –
2021 Q4
12 quarters
SNDX icon
23
Syndax Pharmaceuticals
SNDX
$1.21B
$1.69M 0.61%
128,000
+5,856
+5% +$100K
2024 Q1
3 quarters
VKTX icon
24
Viking Therapeutics
VKTX
$3.24B
$1.57M 0.57%
39,036
– –
2021 Q4
12 quarters
CLOZ icon
25
Panagram BBB-B CLO ETF
CLOZ
$785M
$1.29M 0.47%
47,807
-495,061
-91% -$13.3M
2023 Q3
5 quarters
1
2 3 4

Similar funds

SCA
Sander Capital Advisors Seattle, Washington $189M AUM 13.06% 1-Year Est. Return
FI
FWG Investments Lexington, Kentucky $189M AUM 18.47% 1-Year Est. Return
MFS
Madrid Financial Services Manhattan Beach, California $189M AUM 30.12% 1-Year Est. Return
FRA
FFG Retirement Advisors Centennial, Colorado $189M AUM 16.39% 1-Year Est. Return
CAM
Councilmark Asset Management Knoxville, Tennessee $189M AUM 26.93% 1-Year Est. Return
BAG
Bauman Advisory Group Las Vegas, Nevada $189M AUM
SHC
SALT Holding Corp Wilmington, Delaware $189M AUM 34.63% 1-Year Est. Return
HC
Hara Capital Bellevue, Washington $190M AUM 42.56% 1-Year Est. Return

David M. Knott Jr's Q4 2024 Portfolio in Review

As of Q4 2024, David M. Knott Jr held 98 positions worth $277M, down 2.8% from $285M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

David M. Knott Jr's Q4 2024 filing shows 6 new, 9 increased, 11 reduced and 9 closed positions. Its largest new stake was Collegium Pharmaceutical: 32,927 shares worth $943K. The largest sale was Calumet Specialty Products, an estimated $14.2M.

By sector, the portfolio is most concentrated in Materials at 30% of assets, up from 28% a quarter earlier, followed by Healthcare and Financials.

  • David M. Knott Jr's largest Q4 2024 buy was Collegium Pharmaceutical: 32,927 shares worth $943K.
  • David M. Knott Jr added most to Janus Henderson AAA CLO ETF in Q4 2024, an estimated $25.7M increase.
  • David M. Knott Jr's biggest Q4 2024 reduction was Calumet Specialty Products, cutting an estimated $14.2M.
  • David M. Knott Jr fully exited GSK in Q4 2024, selling an estimated $2.66M.
  • David M. Knott Jr's ten largest holdings make up 77% of its $277M portfolio in Q4 2024.
  • David M. Knott Jr opened 6 new positions and closed 9 in Q4 2024.
  • David M. Knott Jr's portfolio value fell 2.8% quarter-over-quarter to $277M.

Based on David M. Knott Jr's 13F filing for Q4 2024, filed 12 Feb 2025.